Brief: Lantheus Announces Three-Month Extension Of PDUFA Date For LNTH-2501
17/03/2026 20:26
March 17 (Reuters) - Lantheus Holdings Inc LNTH.O: LANTHEUS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR LNTH-2501 (GA 68 EDOTREOTIDE), A PET DIAGNOSTIC IMAGING KIT TARGETING SOMATOSTATIN RECEPTOR-POSITIVE (SSTR+) NEUROENDOCRINE TUMORS (NETS) LANTHEUS HOLDINGS INC - STANDARD REVIEW EXTENSION FOR LNTH-2501 NOT RELATED TO EFFICACY OR SAFETY DATA LANTHEUS HOLDINGS INC - FDA EXTENDS REVIEW OF LNTH-2501 NDA TO JUNE 29, 2026 LANTHEUS HOLDINGS INC - FDA EXTENDS PDUFA GOAL DATE FOR LNTH-2501 TO JUNE 29, 2026 Source text: ID:nGNXbZfXpL Further company coverage: LNTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale